Literature DB >> 424697

Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma.

I M Nilsson, H Walter, M Mikaelsson, H Vilhardt.   

Abstract

Human fraction I-0 (AHF-Kabi) was prepared from plasma from blood donors who had received an i.v. injection of DDAVP (0.2 microgram per kg b.w.) and tranexamic acid (0.01 g per kg b.w.) 15 min before collection of the blood. The factor VIII preparation from such plasma contained twice as much VIII:C,VIIIR:Ag, and VIIIR:RFC as normal fraction I-0. Normal fraction I-0 and DDAVP fraction I-0 were given to 2 patients with severe haemophilia A. The in vivo response of the DDAVP fraction I-0 corresponded to the in vitro values. No differences in survival time were seen. Hence, it is possible to produce factor VIII concentrates with at least double the yield by increasing the factor VIII level in blood donors by i.v. injection of DDAVP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 424697     DOI: 10.1111/j.1600-0609.1979.tb00398.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  4 in total

1.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Authors:  J J Belch; A A Zoma; I M Richards; K McLaughlin; C D Forbes; R D Sturrock
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

2.  Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue.

Authors:  M Porta
Journal:  Diabetologia       Date:  1982-11       Impact factor: 10.122

3.  Fibronectin in blood products--an in vitro and in vivo study.

Authors:  J T Reilly; B A McVerry; M J Mackie
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

Review 4.  Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

Authors:  A Messori; G Longo; M Matucci; M Morfini; P L Ferrini
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.